Ten years on, EMA completes overhaul of biosimilar guidelines
This article was originally published in Scrip
Executive Summary
With the publication of a revised version of its guideline on non-clinical and clinical issues, the EMA has completed the updating of its trio of overarching guidelines on biosimilar products, nearly ten years after they were first published in 2005 and 2006.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.